Trial
NCT02736123
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Pittsburgh
Collaborators
Bristol-Myers Squibb
Condition
Melanoma
Intervention
Nivolumab - Arm A
Why stopped
PI is closing the trial as he will be leaving the University of Pittsburgh Medical Center
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-09-20